Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02706652 · ClinicalTrials.gov registry record
Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients
A clinical trial, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- 8
- Enrollment target
NCT02706652: Clinical Trial study, sponsored by National Cancer Institute (NCI).
NCT02706652 is a clinical trial that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02706652 was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
Background: People's genetic markers and other genetic characteristics can affect their response to drug therapy. Researchers want to screen people for these markers and characteristics. They want to do this before the people are screened for studies at the National Cancer Institute. That should save time that can be lost when people go through the whole screening for a study only to find out they cannot join. The data collected may also be used to select the proper dose of anticancer agents that are being studied. Objective: To screen people for genetic markers and/or baseline characteristics. These will be used to determine if they can enroll in a clinical trial. They may also be used to select the proper dose of anticancer agents that are being tested. Eligibility: Adults 18 and older who are being considered for or being treated in a National Cancer Institute study Design: Participants will have their blood drawn for genetic tests. Some participants will have a cheek swab. Participants genetic data will be stored for future research. It could be shared with other researchers.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-05-22 |
| Est. Completion | 2019-09-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02706652
The ClinicalTrials.gov registry entry for NCT02706652 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02706652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02706652 about?
NCT02706652 is a clinical study titled "Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients". Background: People's genetic markers and other genetic characteristics can affect their response to drug therapy. Researchers want to screen people for these markers and characteristics. They want to do this before the people are screened for studies at the National Cancer Institute. That should sa...
What is the current status of trial NCT02706652?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2018-05-22. Estimated completion is 2019-09-06.
Who is sponsoring clinical trial NCT02706652?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.